Skip to main content

Table 6 Coverage of vaccine genotypes according to histological grades

From: Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination

Vaccine subgroups Histology, n (%) Total
≤CIN1 CIN2 CIN3 Cancer
Hierarchical modela
 6/11b 73 (3.1) 3 (1.6) 0 (0.0) 0 (0.0) 76
 16/18 990 (49.8) 106 (56.1) 176 (74.9) 13 (81.3) 1285
 31/33/45/52/58 732 (30.9) 52 (27.5) 54 (23.0) 2 (12.5) 840
 35/39/51/56/59/66/68 576 (24.3) 28 (14.8) 5 (2.1) 1 (6.3) 610
 6/11/16/18 1063 (44.8) 109 (57.7) 176 (74.9) 13 (81.3) 1361
 6/11/16/18/31/33/45/52/58 1795 (75.7) 161 (85.2) 230 (97.9) 15 (93.8) 2201
Proportional model
 6/11b 73 (3.1) 3 (1.6) 0 (0.0) 0 (0.0) 76
 16/18 904.3 (38.2) 93.5 (49.5) 172.4 (73.3) 14.6 (91.3) 1184.7
 31/33/45/52/58 691.2 (29.2) 60.6 (32.1) 57.7 (24.6) 1.4 (8.8) 811.0
 35/39/51/56/59/66/68 702.5 (29.7) 31.9 (16.9) 4.9 (2.1) 0 (0.0) 739.3
 6/11/16/18 977.3 (41.3) 96.5 (51.1) 172.4 (73.3) 14.6 (91.3) 1260.7
 6/11/16/18/31/33/45/52/58 1668.5 (70.5) 157.1 (83.1) 230.1 (97.9) 16.0 (100.0) 2071.7
Total 2371 (84.3) 189 (6.7) 235 (8.4) 16 (0.6) 2811
  1. Abbreviation: CIN cervical intraepithelial neoplasia
  2. aAccording to hierarchical ranking for CIN2+
  3. bHPV6/11 indicates only HPV6/11 infection, but excludes those coinfected with HPV6/11 and high-risk genotypes. Moreover, HPV6/11 were not included into two attribution models